Q-omics provides the consensus-scored NXPH3 profile across patient tissues and cancer cell-line models. NXPH3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NXPH3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, NXPH3 RNA expression shows 24,341 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, BLCA, and GBM as cancer lineages where NXPH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXPH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXPH3 survival associations across molecular data types. NXPH3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXPH3 RNA expression–survival associations across cancer types. High NXPH3 expression shows unfavorable associations in UVM and LUSC, but favorable associations in BRCA, KIRC, SKCM and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NXPH3 RNA expression.
This table summarizes NXPH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NXPH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXPH3 shows lower tumor expression in BLCA, LUAD, LUSC, COAD and HNSC and higher tumor expression in LIHC. The BLCA box plot shows higher NXPH3 RNA expression in normal versus tumor tissue (log2 FC = −3.368, t-test p < 0.001).
This table shows molecular features associated with NXPH3 in patient tissues and cancer cell lines. In patient samples, NXPH3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NXPH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and OVARY.
